Market News & Trends
Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent
Provectus recently announced the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/678,133, which covers the use of intralesional (aka…
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
Amphastar Pharmaceuticals, Inc. recently announced that the US FDA approved the company’s Abbreviated New Drug Application (ANDA) for Dextrose injection 50% in the 50-mL Luer-Jet…
Micropore Technologies Appoints New Sales Development Director for the Americas
UK-based particle engineering specialist Micropore Technologies has just announced the appointment of Dr. Camden Cutright as its new Sales Development Director based in the US.…
BridgeBio Pharma’s Affiliate QED Therapeutics & Helsinn Group Announce Strategic Co-Development & Commercialization Agreement
BridgeBio Pharma, Inc., through its affiliate QED Therapeutics, Inc., and Helsinn Group recently announced a global collaboration and licensing agreement to further develop and commercialize…
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement With AstraZeneca to Include Drug Product Manufacturing
Ajinomoto Bio-Pharma Services recently announced a manufacturing agreement expansion with AstraZeneca to include drug product manufacturing. This agreement expands the scope of Aji Bio-Pharma’s service…
CureVac’s COVID-19 Vaccine Candidate Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant in Preclinical Challenge Study
CureVac N.V. recently announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of…
Dunad Therapeutics Emerges to Develop Next-Generation Small Molecule Therapeutics Based on First Tuneable Targeted Protein Degradation Technology
Dunad Therapeutics recently emerged to develop next-generation small molecule therapeutics based on its highly differentiated, tuneable, and targeted protein degradation technology. Dunad, secured initial financing…
Visus Therapeutics Initiates Phase 2 Clinical Trial for Presbyopia Treatment
Visus Therapeutics Inc. recently announced the commencement of its Phase 2 clinical trial of BRIMOCHOL topical ophthalmic solution under investigation for the treatment of presbyopia.…
AstraZeneca’s & J&J’s COVID-19 Vaccines Manufacturing Face Viral Vector Shortages
The latest wave of COVID-19 vaccines - those from AstraZeneca and Johnson & Johnson (J&J) - are recombinant vector vaccines, which are a different molecule…
Catalent Signs Drug Development Agreement With Cybin Inc
Catalent recently announced it has signed an agreement with Cybin Inc. to apply Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology for the delivery of…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….